Epigenetic Regulation of the Nitric Oxide Pathway, 17-α Hydroxyprogesterone Caproate, and Recurrent Preterm BirthFunding This study was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development 5K23HD067224 (Dr. Manuck), NIMHD 1R01MD011609 (Dr. Manuck) and a H.A. and Edna Benning Endowed Professorship (Dr. Varner). This study was also supported by the Translational and Clinical Sciences Institute grant support (ULTR001111 from the Clinical and Translational Science Award program of the National Center for Advancing Translational Sciences, National Institutes of Health) and the NIEHS (T32ES007018).
03 November 2017
10 November 2017
14 December 2017 (eFirst)
Objective We sought to evaluate nitric oxide pathway placental gene expression and the epigenome (CpG methylation) among women receiving 17-α hydroxyprogesterone caproate (17-OHPC) with and without recurrent preterm birth (PTB).
Study Design This was a case–control study. We prospectively recruited women with ≥ 1 prior singleton spontaneous PTB <34 weeks receiving 17-OHPC. DNA and RNA were isolated from placentas. RNA abundance (gene expression) and the methylome were analyzed for 84 genes in nitric oxide pathways. Women with recurrent PTB <34 weeks (cases) were compared with those delivering at term (controls). Statistical analysis included multivariable models with Bonferroni's corrected p-values.
Results In this study, 17 women met inclusion criteria; 7 preterm cases (delivered at 22.6 ± 2.9 weeks) and 10 term controls (delivered at 38.5 ± 0.8 weeks). Groups had similar PTB history, race/ethnicity, and socioeconomic risk factors for PTB. Twenty-seven nitric oxide genes displayed differential expression (p < 0.05 and q < 0.10) when comparing placentas from preterm cases and term controls; all were downregulated in preterm cases. Eight hundred sixty corresponding CpG sites were differentially methylated between the preterm cases and term controls (Bonferroni's p-value <0.05).
Conclusion CpG methylation and gene expression patterns in nitric oxide pathway genes differ among placentas from recurrent PTB compared with term birth following 17-OHPC exposure.
Keywords17-α hydroxyprogesterone caproate - epigenetics - gene expression - nitric oxide - recurrent preterm birth
This study was presented in part at the Society for Maternal Fetal Medicine's 37th Annual Meeting (Las Vegas, NV), January 26, 2017, as a poster presentation, final abstract ID# 379.
- 1 Adams MM, Elam-Evans LD, Wilson HG, Gilbertz DA. Rates of and factors associated with recurrence of preterm delivery. JAMA 2000; 283 (12) 1591-1596
- 2 Meis PJ, Klebanoff M, Thom E. , et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348 (24) 2379-2385
- 3 Timofeev J, Singh J, Istwan N, Rhea D, Driggers RW. Spontaneous preterm birth in African-American and Caucasian women receiving 17α-hydroxyprogesterone caproate. Am J Perinatol 2014; 31 (01) 55-60
- 4 Manuck TA, Esplin MS, Biggio J. , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN-PBR). Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth. Am J Obstet Gynecol 2016; 214 (03) 376.e1-376.e8
- 5 Manuck TA, Stoddard GJ, Fry RC, Esplin MS, Varner MW. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system. Am J Obstet Gynecol 2016; 215 (05) 622.e1-622.e8
- 6 Manuck TA, Watkins WS, Esplin MS. , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN-PBR). Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth: a case-control study. BJOG 2017 DOI: 10.1111/1471-0528.14485
- 7 Caritis SN, Venkataramanan R, Thom E. , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network and Obstetric-Fetal Pharmacology Research Units Network. Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth. Am J Obstet Gynecol 2014; 210 (02) 128.e1-128.e6
- 8 Manuck TA, Watkins WS, Moore B. , et al. Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention. Am J Obstet Gynecol 2014; 210 (04) 321.e1-321.e21
- 9 Committee opinion no 611: method for estimating due date. Obstet Gynecol 2014; 124 (04) 863-866
- 10 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research Electronic Data Capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42 (02) 377-381
- 11 Winn VD, Haimov-Kochman R, Paquet AC. , et al. Gene expression profiling of the human maternal-fetal interface reveals dramatic changes between midgestation and term. Endocrinology 2007; 148 (03) 1059-1079
- 12 Chwalisz K, Winterhager E, Thienel T, Garfield RE. Synergistic role of nitric oxide and progesterone during the establishment of pregnancy in the rat. Hum Reprod 1999; 14 (02) 542-552
- 13 Selles J, Polini N, Alvarez C, Massheimer V. Nongenomic action of progesterone in rat aorta: role of nitric oxide and prostaglandins. Cell Signal 2002; 14 (05) 431-436
- 14 Simoncini T, Mannella P, Fornari L. , et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 2004; 145 (12) 5745-5756
- 15 Simoncini T, Caruso A, Garibaldi S. , et al. Activation of nitric oxide synthesis in human endothelial cells using nomegestrol acetate. Obstet Gynecol 2006; 108 (04) 969-978
- 16 Pang Y, Dong J, Thomas P. Progesterone increases nitric oxide synthesis in human vascular endothelial cells through activation of membrane progesterone receptor-α. Am J Physiol Endocrinol Metab 2015; 308 (10) E899-E911
- 17 Sladek SM, Magness RR, Conrad KP. Nitric oxide and pregnancy. Am J Physiol 1997; 272 (2 Pt 2): R441-R463
- 18 Buxton IL, Milton D, Barnett SD, Tichenor SD. Agonist-specific compartmentation of cGMP action in myometrium. J Pharmacol Exp Ther 2010; 335 (01) 256-263
- 19 Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999; 103 (03) 401-406
- 20 MacRitchie AN, Jun SS, Chen Z. , et al. Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ Res 1997; 81 (03) 355-362
- 21 Ricciardolo FL, Nijkamp FP, Folkerts G. Nitric oxide synthase (NOS) as therapeutic target for asthma and chronic obstructive pulmonary disease. Curr Drug Targets 2006; 7 (06) 721-735
- 22 Catov JM, Scifres CM, Caritis SN, Bertolet M, Larkin J, Parks WT. Neonatal outcomes following preterm birth classified according to placental features. Am J Obstet Gynecol 2017; 216 (04) 411.e1-411.e14
- 23 Morgan TK. Role of the placenta in preterm birth: a review. Am J Perinatol 2016; 33 (03) 258-266
- 24 Izumi H, Garfield RE. Relaxant effects of nitric oxide and cyclic GMP on pregnant rat uterine longitudinal smooth muscle. Eur J Obstet Gynecol Reprod Biol 1995; 60 (02) 171-180
- 25 Izumi H, Yallampalli C, Garfield RE. Gestational changes in L-arginine-induced relaxation of pregnant rat and human myometrial smooth muscle. Am J Obstet Gynecol 1993; 169 (05) 1327-1337
- 26 Yallampalli C, Izumi H, Byam-Smith M, Garfield RE. An L-arginine-nitric oxide-cyclic guanosine monophosphate system exists in the uterus and inhibits contractility during pregnancy. Am J Obstet Gynecol 1994; 170 (1 Pt 1): 175-185
- 27 Vora NL, Smeester L, Boggess K, Fry RC. Investigating the role of fetal gene expression in preterm birth. Reprod Sci 2017; 24 (06) 824-828
- 28 Lysell J, Stjernholm Vladic Y, Ciarlo N, Holmgren A, Sahlin L. Immunohistochemical determination of thioredoxin and glutaredoxin distribution in the human cervix, and possible relation to cervical ripening. Gynecol Endocrinol 2003; 17 (04) 303-310
- 29 Sahlin L, Wang H, Stjernholm Y. , et al. The expression of glutaredoxin is increased in the human cervix in term pregnancy and immediately post-partum, particularly after prostaglandin-induced delivery. Mol Hum Reprod 2000; 6 (12) 1147-1153
- 30 Hirota Y, Acar N, Tranguch S. , et al. Uterine FK506-binding protein 52 (FKBP52)-peroxiredoxin-6 (PRDX6) signaling protects pregnancy from overt oxidative stress. Proc Natl Acad Sci U S A 2010; 107 (35) 15577-15582
- 31 Li L, Shoji W, Oshima H, Obinata M, Fukumoto M, Kanno N. Crucial role of peroxiredoxin III in placental antioxidant defense of mice. FEBS Lett 2008; 582 (16) 2431-2434
- 32 Hannan NJ, Beard S, Binder NK. , et al. Key players of the necroptosis pathway RIPK1 and SIRT2 are altered in placenta from preeclampsia and fetal growth restriction. Placenta 2017; 51: 1-9
- 33 Fajardy I, Moitrot E, Vambergue A, Vandersippe-Millot M, Deruelle P, Rousseaux J. Time course analysis of RNA stability in human placenta. BMC Mol Biol 2009; 10: 21
- 34 Caritis SN, Sharma S, Venkataramanan R. , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation. Am J Obstet Gynecol 2011; 205 (01) 40.e1-40.e8